Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38724
Title: | A long‐term follow‐up of early breast cancer patients treated with photobiomodulation during conventional fractionation radiotherapy in the prevention of acute radiation dermatitis | Authors: | ROBIJNS, Jolien LODEWIJCKX, Joy CLAES, Marithe Lenaerts, Melissa Van Bever, Leen Claes, Stefan Pannekoeke, Luc Verboven, Katleen Noé, Leen MAES, Annelies BULENS, Paul MEBIS, Jeroen |
Issue Date: | 2022 | Publisher: | Source: | LASERS IN SURGERY AND MEDICINE, | Status: | In press | Abstract: | Objectives: The evidence demonstrating the efcacy of photobiomodulation (PBM) therapy for preventing and managing acute radiation dermatitis (ARD) is growing steadily. The question that arises from many clinicians is, if PBM is safe for oncologic patients. This study aimed to evaluate the diseasefree survival (DFS), cancerfree survival (CFS), and overall survival (OS) of breast cancer patients treated with PBM for ARD. Methods: Clinical data of 120 breast cancer patients treated with prophylactic PBM (n = 60, 2x/week, 808−905 nm, 4 J/cm 2) or placebo (n = 60) during conventional fractionation (CF) radiotherapy (RT) between April 2015 and June 2017 were retrospectively analyzed (TRANSDERMIS trial). During followup (April 2015 to May 2022), patients underwent a complete clinical evaluation every 6 months and blood analysis and mammography yearly in the rst 5 years after the end of RT. The DFS, CFS, and OS were estimated. Results: At a median followup time of 66 months (range 4−81), there was no signicant difference in DFS (73.7% vs. 98.3%, resp., p = 0.54), CFS (68.4% vs. 77.8%, resp., p = 0.79), and OS (87.9% vs. 98.3%, resp., p = 0.30) between the placebo and PBM group. Conclusions: This paper is the rst to describe the results of a longterm followup in earlystage breast cancer patients who underwent PBM for ARD. Results suggest that using PBM in breast cancer patients undergoing CF RT does not inuence the locoregional recurrence, the development of new primary tumors, or OS. | Keywords: | Photobiomodulation;Oncology;Supportive care;PBM;Safety;Follow-up;Cancer | Document URI: | http://hdl.handle.net/1942/38724 | ISSN: | 0196-8092 | e-ISSN: | 1096-9101 | DOI: | 10.1002/lsm.23608 | ISI #: | 000862600000001 | Rights: | 2022 Wiley Periodicals LLC. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Robijns_2022_safety.pdf Restricted Access | Published version | 422.07 kB | Adobe PDF | View/Open Request a copy |
Authorversion.pdf | Non Peer-reviewed author version | 657.35 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.